Laigo Bio at Utrecht Science Park raises €11.5 million in investments
Laigo Bio, a start-up located at Utrecht Science Park in the Life Sciences Incubator building, announced today that it has raised €11.5 million in investments from a large number of leading investors.
Laigo Bio will use the investment to further develop various therapies based on its patented SureTAC™ technology. These include oncology programs, which the company intends to prepare for clinical trials, as well as three immunology products still in the discovery phase. The latter addresses specific immune and autoimmune indications, and the immune response following transplants.
The SureTAC™ technology, developed by the lab of Prof. Madelon Maurice at UMC Utrecht and the Oncode Institute, enables the targeted degradation of membrane proteins that play a role in diseases but have long been considered undruggable. Laigo Bio’s SureTACs demonstrate promising in vitro and in vivo efficacy.
Kurma Partners (Paris) and Curie Capital (Amsterdam) led the financing round. Other investors include the Oncode Bridge Fund, Angelini Ventures, Eurazeo, Argobio Studio, ROM Utrecht Region, and Cancer Research Horizons, part of Cancer Research UK.
Finally, Laigo Bio announced the appointment of Dr. Matthew Baker as CEO. Dr. Baker has an impressive career in biotech company management, working specifically in the field of inflammatory diseases and oncology for over twenty years.
It is wonderful to see that the unique Life Sciences & Health ecosystem of Utrecht Science Park is contributing to the further development of this company through a technology developed at UMC Utrecht.
For more information and the official press release, click here.